Big Pharma has discovered the god molecule, and it wants to put it in a nasal spray. Scary names: Psilocybin, MDMA analogues, synthetic DMT, LSD derivatives, the same class of substances that once promised to expand consciousness, dissolve the ego, and reconnect humanity with the cosmos are now being refined, patented, and lined up for FDA approval as treatments for depression, PTSD, anxiety, and half a dozen other conditions. The political weather is favourable. Startups have priority review vouchers. Major companies are writing billion-dollar checks. Clinics that already sell ketamine nasal spray are expected to add the rest of the psychedelic candy box. A psychiatrist's office, as one observer put it, may soon resemble the backpack of a high-end dealer at Burning Man.
The sales pitch is familiar: faster than SSRIs, effective for the treatment-resistant, potentially lasting months after a small number of doses. Some patients will improve. Some already have in carefully controlled trials. That is not the whole story, and it is not a sufficient reason to industrialise substances whose primary effect is to temporarily dismantle ordinary consciousness.
These compounds do not merely adjust neurotransmitter levels. They produce intense, often overwhelming subjective experiences: mystical states, ego dissolution, sudden shifts in identity, memory, and worldview. Aldous Huxley noted that the person who returns through the Door in the Wall is never quite the same. That is not a bug of the experience; it is the point. Turning such an experience into a billable medical procedure requires pretending that the profound can be standardised, the unpredictable managed, and the existential side-effects absorbed by a short course of "psychological support." The industry is already trying to strip full therapy out of the model to lower costs. The risks do not shrink to match.
History offers a crude but useful caution. When LSD moved from the laboratory into the culture in the 1960s, it did not produce a generation of calmly integrated visionaries. It produced brilliant work and also fragmentation, paranoia, broken bands, ruined careers, and a fair amount of permanent damage. The Beatles are the soft version of the warning. What began as experimentation and creative stimulus ended in dissolution, spiritual seeking that often looked more like spiritual confusion, and a cultural moment that celebrated the dissolution of ordinary boundaries without much interest in what happened to the people who could not put themselves back together. Scale that up, remove the residual social stigma, and deliver it through psychiatric clinics with the imprimatur of medicine, and the adverse events will not remain anecdotal.
There are practical problems as well. Informed consent for a drug that can rewrite a person's sense of self is not the same as consent for a blood-pressure medication. Families are often unprepared for the person who returns different. Integration support is uneven. The same compounds are already circulating outside clinical settings in churches, retreats, and gray-market channels; medicalisation will not wall them off, it will normalise them further. The marijuana precedent is instructive: medical claims opened the door, recreational use followed, and the original therapeutic framing became secondary. Adverse outcomes did not disappear; they simply became background noise.
None of this requires denying that some patients with severe, treatment-resistant conditions may benefit under tightly controlled conditions with experienced guides. It does require scepticism about the industrial ambition now on display. Depression and trauma are real and often devastating. That does not mean the correct response is to medicalise tools that deliberately destabilise the mind and then hope the paperwork and the billing codes will contain the consequences. A society already struggling with meaning, attention, and social cohesion is not obviously improved by making chemical ego-death a routine outpatient procedure.
The Beatles survived their experiments, more or less. Not everyone did. Turning the same class of substances into the next pharmaceutical growth category treats that history as irrelevant colour rather than data. It is a bad way to go. Or as was said in the 1960s: a bad trip, man!
https://spectator.com/article/big-pharma-wants-to-sell-you-psychedelic-drugs/